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Abstract
Objective To examine the association between chronic use of proton
pump inhibitors (PPIs) and risk of hip fracture.
Design Prospective cohort study.
Setting Nurses’ Health Study, which originally recruited from the 11
most populous states in the US.
Participants 79 899 postmenopausal women enrolled in the Nurses’
Health Study who provided data on the use of PPIs and other risk factors
biennially since 2000 and were followed up to 1 June 2008.
Main outcome measure Incident hip fracture
Results During 565 786 person years of follow-up, we documented 893
incident hip fractures. The absolute risk of hip fracture among regular
users of PPIs was 2.02 events per 1000 person years, compared with
1.51 events per 1000 person years among non-users. Compared with
non-users, the risk of hip fracture among women who regularly used
PPIs for at least two years was 35% higher (age adjusted hazard ratio
1.35 (95% confidence interval 1.13 to 1.62)), with longer use associated
with increasing risk (Ptrend<0.01). Adjustment for risk factors, including
body mass index, physical activity, and intake of calcium did not
materially alter this association (hazard ratio 1.36 (1.13 to 1.63)). These
associations were also not changed after accounting for reasons for PPI
use. The relation between PPI use and fracture differed by smoking
history (Pinteraction=0.03). Among current and former smokers, PPI use was
associated with greater than 50% increase in risk of fracture, with a
multivariate hazard ratio for fracture of 1.51 (1.20 to 1.91). In contrast,
among women who never smoked there was no association (multivariate
hazard ratio 1.06 (0.77 to 1.46)). In a meta-analysis of these results with
10 prior studies, the pooled odds ratio of hip fracture associated with
PPI use was 1.30 (1.25 to 1.36).
Conclusion Chronic use of PPIs is associated with increased risk of
hip fracture, particularly among women with a history of smoking.
Introduction
Proton pump inhibitors (PPIs) are among the most commonly
used drugs worldwide.
1 In the US, PPI use increased
dramaticallysince2003aftertheFoodandDrugAdministration
approved the drugs for “over the counter” use. Primarily used
for the treatment of heartburn symptoms, gastroesophageal
reflux, or peptic ulcer, PPIs antagonise hydrogen-potassium
adenosinetriphosphatasepumpslocatedongastricparietalcells,
2
thereby reducing acid production to a greater extent than
histaminereceptor-2(H2)blockers.
3Althoughshorttermuseof
PPIs is generally well tolerated, concern has grown over
potentialassociationbetweenlongtermuseandbonefractures,
especially of the hip, which are known to be associated with
substantialmorbidityandmortality.
4-6PPIsmayinhibitcalcium
absorption,
7directlyinterferewithosteoclastfunction,
8orinduce
hypergastrinaemia, resulting in reductions in bone mineral
density related to hyperparathyroidism.
9
Several studies have investigated the association between PPI
useandriskofhipfracture.
3 10-17Manyofthesestudieshavehad
important limitations, including retrospective design,
10 12-14 16 17
inability to control for important dietary and lifestyle
confounders,
3 10 12-14 16 small sample size,
17 and limited
ascertainment of PPI exposure.
11 None the less, in May 2010
the Food and Drug Administration issued a warning regarding
a potential association, but acknowledged that more data were
needed.
18
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Research
RESEARCHWe therefore sought to examine the association between long
term PPI use and risk of hip fracture among postmenopausal
womenenrolledinalargeprospectivecohort,theNurses’Health
Study, where detailed information about dietary and lifestyle
factors are collected biennially.
19-23 This cohort offered us an
opportunity to examine PPI use in the context of other dietary
and lifestyle risk factors that may either confound or modify its
associationwithfracture.Wealsoconductedasystematicreview
of our findings with prior studies to provide a more
comprehensive estimate of the association.
Methods
Study population
The Nurses’ Health Study is a prospective cohort that began in
1976 when 121 700 US female registered nurses aged 30–55
years completed a mailed health questionnaire. We sent
questionnaires to study participants every two years to update
information and identify new cases of fracture; follow-up has
consistentlyexceeded90%.Avalidatedassessmentofphysical
activity is administered every two years,
24 and a validated
semi-quantitativefoodfrequencyquestionnaireisadministered
every four years.
25 26 The institutional review board at the
Brigham and Women’s Hospital approved this study.
Outcome ascertainment
In 1982 participants were first asked to report all previous hip
fractures (date, bone site, and circumstances). Subsequently, in
each biennial questionnaire, women were specifically asked,
“Over the past two years have you had a hip fracture?”
Participants who responded “yes” received a follow-up
questionnaire asking them to “describe the circumstances that
caused the hip fracture, bone site, and the month/year of
fracture.”Weincludedcasesofhipfracturethatwereassociated
with reports of low or moderate trauma (such as slipping on ice
or falling from the height of a chair). We excluded fractures
associatedwithhightrauma(suchasfromskiingorfallingdown
a flight of stairs—about 15% of the reports). In an analysis of
30 study participants, all self reported fractures were validated
by medical record review.
27
Assessment of proton pump inhibitor and H2
blocker use
In1994participantswereaskedwhethertheyhadregularlyused
“cimetidine(Tagamet)orranitidine(Zantac)”overtheprevious
two years. In the 1996, 1998, and 2000 questionnaires,
participants were asked whether, over the previous two years,
they had regularly used “cimetidine (Tagamet) or other H2
blockers (e.g. Zantac, Pepcid, etc).” In 2002, 2004, and 2006
participants were asked whether, over the previous two years,
they had regularly used any “H2 blockers (e.g. Zantac,
cimetidine, Pepcid, Axid, etc.).” In 2000 and 2002 participants
were asked whether, over the previous two years, they had
regularly used “Prilosec or Prevacid.” In 2004 and 2006,
participants were asked whether, over the previous two years,
they had regularly used “Prilosec, Prevacid (lansoprazole),
Protonix, Nexium, or Aciphex.” Women were not asked about
dose or to specify the brand or type of PPI.
Other covariates
On each biennial questionnaire, women were asked about their
menopause status; body weight; time spent in recreational and
leisure time activities; smoking status; alcohol use; daily
cigarette consumption; use of hormone replacement therapy,
thiazidediuretics,corticosteroids,bisphosphonates,andcalcium
supplements; and incident diagnosis of osteoporosis.
Participants’ self reported body weight and physical activity
have been previously validated.
28 Using a validated
semi-quantitative food frequency questionnaire,
25 26 we
calculated total intake of calcium and vitamin D from the
reported consumption of foods and use of multivitamins and
specific vitamin and mineral supplements. As in previous
analyses, we used cumulatively averaged nutrient intake, body
weight, and physical activity to reduce within person variation
andtoreflectlongtermexposure.
29Weincludedthesevariables
according to categories which we have previously shown to be
most strongly associated with risk of hip fracture.
21 29 30
Reasons for PPI use
We considered the possibility that the previously observed
association between PPI use and risk of hip fracture could be
relatedtothereasonforuseofthedrug.In2000,asupplemental
questionnaire that inquired about the frequency, severity, and
duration of heartburn and acid regurgitation was sent to 11 080
participantsintheNurses’HealthStudywithasthmaandchronic
obstructive pulmonary disease and 11 080 randomly selected
controls (response rate 86%, n=19 060).
30 Detailed description
and validation of this questionnaire were previously reported.
29
Amongtherespondents,16478providedcompleteinformation
regarding PPI use and the reasons for it and therefore were
eligible for our analysis.
Statistical analysis
Atbaseline,weincludedpostmenopausalwomenwhoreturned
the 2000 biennial questionnaire in which they were first
specifically queried about their use of PPIs. We excluded
participantswhohadpreviouslyreportedhipfractureorcancer.
Aftertheseexclusions,79899womenwereeligibleforanalysis.
Person time for each participant was calculated from the date
of return of the baseline questionnaire to the date of first hip
fracture,dateoflastquestionnairereport,deathfromanycause,
or last day of outcome ascertainment (1 June 2008), whichever
came first. Women were defined as PPI users if they responded
that they had regularly used PPI in the previous two years. We
also assessed consistent use by restricting our analysis to
follow-up after 2002 and examining women who reported
regularPPIuseonthetwopreviousquestionnaires(thatis,2000
and2002atbaseline)comparedwithwomenwhodidnotreport
use on these questionnaires.
31
WeusedCoxproportionalhazardsmodellingusingtimevarying
variables with the most updated information for PPI use and
other covariates before each two year interval to calculate
adjusted hazard ratios and 95% confidence intervals. We also
examined the association between PPI use and hip fracture
according to strata of other risk factors. We used SAS version
9.1.3(CaryNC,USA)fortheseanalyses.AllPvaluesweretwo
sided,andvalues<0.05wereconsideredstatisticallysignificant.
Systematic review of results with prior studies
We also conducted a meta-analysis of our data with the results
of published studies assessing the relation between chronic PPI
use and risk of hip fracture. We included the seven studies that
were cited by the Food and Drug Administration in the May
2010 report.
18 In addition, we conducted a Medline search (last
accessed 20 December 2010) with the search terms “proton
pump inhibitor” AND “fracture” and identified four additional
studies for inclusion.
12 32-34 We excluded the study by Roux et
al
34 since the primary outcome was vertebral fracture and there
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RESEARCHwere only 11 cases of hip fracture reported. In addition, three
studies
3 16 32 used the UK General Practice Research Database,
although there may have been differences in the populations
included. Thus, we included all three studies in our
meta-analysis but also conducted sensitivity analyses in which
we computed the pooled odds ratio with inclusion of only one
of the three studies each in turn.
We used the adjusted odds ratio for hip fracture as our
metameter of interest. However, in two studies, data were
reported only as adjusted hazard ratios. For the study by Gray
et al,
11 we estimated the odds ratio by calculating the numbers
of cases in the control and exposed groups using the reported
incident rate and person time. For the study by Yu et al,
17
because the number of cases of fracture was not reported or
provided by the authors after our request, we used the reported
hazard ratio. We pooled estimates by random effects
meta-analysis according to the method of Desimonian and
Laird.
35WeusedtheQstatistictoestimateheterogeneityamong
the studies. We used Comprehensive Meta-Analysis software
(Biostat,EnglewoodNJ,USA)fortheseanalyses(seeappendix
on bmj.com).
Results
Among 79 899 postmenopausal women, we documented 893
incident hip fractures over 565 786 person years of follow-up.
In 2000, 6.7% of women regularly used a PPI, rising to 18.9%
by 2008. Compared with participants who did not regularly use
a PPI, regular users had a higher body mass index, were less
physically active, consumed less alcohol, were more likely to
have a history of osteoporosis, and were more likely to use
hormonereplacementtherapy,thiazidediuretics,corticosteroids,
or bisphosphonates (table 1⇓).
The absolute risk of hip fracture among regular users of PPIs
was 2.02 events per 1000 person years, compared with 1.51
eventsper1000personyearsamongnon-users.Comparedwith
non-users, regular users of PPIs had a 35% increase in risk of
hip fracture (age adjusted hazard ratio 1.35 (95% confidence
interval 1.13 to 1.62)) (table 2⇓). The relation remained largely
unchanged even after adjusting for body mass index (hazard
ratio 1.45 (1.21 to 1.73)) or intake of dietary and supplemental
calcium (hazard ratio 1.35 (1.12 to 1.62)). After additionally
accountingforotherriskfactorsforfracture—includingsmoking
status,physicalactivity,andhistoryofosteoporosis—theserisk
estimates were not materially altered (hazard ratio 1.37 (1.14
to 1.64)). We also did not observe any change in risk after
adjusting for concomitant use of drugs known to affect the risk
of fracture, including hormone replacement, bisphosphonates,
corticosteroids,andthiazidediuretics(fullyadjustedmultivariate
hazard ratio 1.36 (1.13 to 1.63)).
We first asked participants in the Nurses’ Health Study about
PPIuseinthe2000questionnaire.Weconsideredthepossibility
that women who reported use in 2000 had probably used PPIs
for varying durations. Thus, we conducted an analysis in which
we excluded women who reported use in 2000 and restricted
the analysis to follow-up after 2002. Women who first reported
PPI use in 2002 had a fully adjusted hazard ratio of hip fracture
of 1.42 (1.14 to 1.76) compared with women who had not used
PPIs. To test if the association between PPI use and fracture
might be due to its effect on gastric acid suppression, we
examined regular use of less potent acid suppressors, H2
blockers, in relation to risk of fracture after excluding
participants who used PPIs. Compared with PPI use, regular
use of H2 blockers was associated with a more modest risk of
fracture (fully adjusted hazard ratio 1.23 (1.02 to 1.50) v
non-use).
The risk of hip fracture associated with PPI use increased with
the duration of use (Ptrend<0.01) (table 3⇓). Compared with
non-users, the fully adjusted hazard ratios of fracture were 1.36
(1.12to1.65)forwomenwithtwoyears’useofPPIs,1.42(1.05
to 1.93) for four years’ use, and 1.55 (1.03 to 2.32) for six to
eight years’ use. To assess consistent use, we focused our
analyses on women who reported PPI use in two consecutive
biennial follow-up questionnaires and compared the incidence
of fracture among women who did not use PPIs in two
consecutiveintervals.Amongconsistentusers,thefullyadjusted
hazard ratio of fracture was 1.42 (1.06 to 1.88).
We also considered time since stopping PPI use in relation to
risk of fracture (table 4⇓). Although risk persisted for women
whostoppedPPIusewithintwoyears,womenwhohadstopped
use more than two years previously had a fully adjusted hazard
ratio of fracture of 1.10 (0.63 to 1.92), similar to that of women
who had never used a PPI.
We evaluated potential differences in the influence of PPI use
according to strata of known risk factors (table 5⇓). The risk of
hip fracture seemed to differ according to history of cigarette
smoking(Pinteraction=0.03).Amongwomenwhoeitherpreviously
or currently smoked, the fully adjusted hazard ratio of fracture
was 1.51 (1.20 to 1.91). In contrast, there was no significant
association between PPI use and risk of fracture among women
who never smoked (fully adjusted hazard ratio 1.06 (0.77 to
1.46)). The effect of PPIs was not modified by strata defined
by age, body mass index, use of hormone replacement therapy,
use of corticosteroids, history of osteoporosis, or intake of
calcium (all Pinteraction>0.10).
We considered the possibility that the observed association of
PPIs with hip fracture could be related to the reason for taking
the drug. In 2000 we collected detailed information about
symptomsofacidrefluxandheartburnfrom16478participants
through a supplementary questionnaire. Among these
participants,thefullyadjustedhazardratiooffractureassociated
with regular use of PPIs was 1.45 (1.01 to 2.10) and was not
materially altered after accounting for the reason for PPI use.
Specifically,thefullyadjustedhazardratiooffracturewas1.53
(1.04 to 2.25) after adjusting for heartburn; 1.37 (0.94 to 2.02)
after adjusting for acid reflux; and 1.39 (0.96 to 2.02) after
adjusting for peptic ulcer disease. These effect estimates did
not vary according to the participants’ case or control status
(Pinteraction=0.57). Moreover, in separate analyses, there were no
independent associations between reported heartburn, acid
reflux, or peptic ulcer disease and risk of hip fracture (data not
shown). We also conducted several sensitivity analyses to
confirm that our associations were robust (see appendix on
bmj.com).
Systematic review
Finally, we performed a systematic review of our results with
the 10 published epidemiological studies on risk of hip fracture
with chronic use of PPIs (see table in appendix).
3 10-14 16 17 33 34
There was moderate heterogeneity across studies (Qstatistic=22.0;
I2=50.0, P=0.02). Among the 1 562 862 individuals included
within the 11 studies, the pooled odds ratio of hip fracture
associated with PPI use was 1.28 (1.19 to 1.37) using a random
effects meta-analysis (figure⇓). We observed similar results
using a fixed effects meta-analysis (odds ratio 1.30 (1.25 to
1.36)). We also computed the pooled odds ratio with inclusion
of only one of the three studies from the UK General Practice
Research Database each in turn.
3 16 32 Using a random effects
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RESEARCHmeta-analysis, we found the pooled odds ratio of hip fracture
associated with PPI use was 1.30 (1.20 to 1.40) including the
study of Yang et al,
3 1.27 (1.18 to 1.36) including de Vries et
al,
32 and 1.25 (1.15 to 1.37) including Kaye et al.
16
Discussion
Findings from this large prospective cohort of postmenopausal
womenandasystematicreviewofepidemiologicalstudiesshow
a significant association between regular use of PPIs and risk
ofhipfracture.Furthermore,ourresultsshowthatriskincreases
with longer duration of PPI use and seems to be confined to
womenwithahistoryofsmoking.Theseassociationsremained
largely unchanged even after carefully adjusting for factors
associated with both use of PPI and risk of hip fracture, as well
as the reasons for PPI use. The increased risk of hip fracture
was no longer evident after PPI use had been stopped for two
or more years.
Comparison with other studies
Our results are supported by several prior findings, including
recentmeta-analyses.
36 37Intwolargecase-controlstudiesbased
on the UK General Practice Research Database and the Kaiser
Permanente,NorthernCalifornia,integratedhealthcaredelivery
system,
3 10 PPI use for at least one year was associated with an
increase in risk of hip fracture of similar magnitude to our risk
estimates. Because these case-control studies had limited
information on several key risk factors for fracture, our cohort
analysis, with careful adjustment for such factors, significantly
extends these findings.
Our results do, however, contrast with data from other studies.
InanindependentanalysisoftheUKGeneralPracticeResearch
Database, PPI use was not associated with hip fracture.
16
However, this study was limited to individuals without risk
factors for hip fracture. More recently, in the Women’s Health
Initiative, PPI use was associated with risk of total fracture,
spinefracture,andwristfracture,butnothipfractureorchanges
in bone mineral density.
11 However, data on PPI use was
collected only in 1997 and 2000, when the prevalence of use
was extremely low (2.1% in 1997, 5.8% in 2000). By not
accounting for the dramatic increase in use of these drugs after
2000, the researchers may have misclassified PPI exposure and
led to their finding no association for hip fracture. In support
of this explanation, we also observed no significant association
with risk of hip fracture when we considered PPI use only
according to our baseline assessment in 2000 (multivariate
adjusted hazard ratio 1.20 (0.94 to 1.54)). Moreover, it is
possible that the association between PPI and fracture may be
mediated independently of changes in bone mineral density.
Consistent with prior studies,
3 10 we did observe a significant,
though more modest, association with hip fracture among
women who used H2 blockers, which are less potent acid
suppressors than PPI. These data suggest mechanistically that
PPIs may increase fracture risk through their effect on gastric
acid secretion, which could impair absorption of calcium.
However, in our analysis, as well as others,
11 risk of fracture
didnotseemtobemodifiedbyintakeofcalcium.Thisisfurther
supported by two recent studies that showed no association
between PPI use and gut calcium absorption.
38 39 Moreover,
several studies have not observed a significant association
between PPI use and short term changes in bone mineral
density.
11 17 40
Nevertheless, our finding that the risk of fracture was confined
to women with a history of smoking, an established risk factor
for fracture,
19 may provide additional mechanistic insight.
Smoking has been shown to inhibit calcium absorption.
41 Thus,
smokingandPPIsmayhaveasynergisticeffectonfracturerisk
mediated by impaired calcium absorption. In addition,
experimentalstudieshavepostulatedthatbothPPIsandsmoking
influence osteoclast function,
8 42 perhaps suggesting a shared
negativeeffectonboneremodelling.Futureexperimentalstudies
oradditionalanalysesofothercohortsshouldalsoexaminejoint
exposure to PPI use and smoking.
Strengths and limitations of the study
Animportantstrengthofourstudycomparedwithprioranalyses
was the detailed, prospectively collected, and validated
information on several potential confounding risk factors,
including body mass index, use of postmenopausal hormones,
smoking, calcium intake, and physical activity. In our cohort,
each of these factors has previously been associated with risk
of fracture.
19-23 Thus, we were able to carefully adjust for these
potential confounders to determine more clearly the specific
effect of PPI use on the risk of fracture. We were also able to
minimiseconfoundingbydiseaseindicationorprotopathicbias
by accounting for the clinical reason for PPI use.
Most prior studies, including the two large case-control studies
that showed strong associations,
3 10 had a substantial amount of
incomplete information on body mass index and smoking and
wereunabletoassessadequatelydiet,physicalactivity,andthe
indication for PPI use. Thus, our results provide additional
assurance that these previously reported associations are not
due to incomplete adjustment of confounding factors. In our
analysis, we also collected information on PPI use every two
years and used time-varying PPI exposure in our Cox models.
Thus, our study was uniquely able to account for the effect of
changes in PPI use and the substantial increase in PPI use over
thepastdecadeonriskoffracture,minimisingmisclassification
of exposure. Lastly, despite significant heterogeneity between
studies,oursystemicreviewandmeta-analysis,whichincluded
1 562 862 patients, showed consistent results.
Our study has several limitations. Firstly, we did not have
informationaboutPPIuseinparticipantsbefore2000.However,
the prevalence of use in 2000 was low (6.7%) and steadily
increasedthrough2008,reflectingseculartrends.Thus,PPIuse
before2000wasprobablyextremelylow.Nonetheless,wedid
observe a significant relation between duration of PPI use and
riskofhipfracture;anymisclassificationofPPIusebefore2000
would be expected to attenuate our risk estimates. Moreover,
when we limited our analysis to new users of PPI beginning in
2002, we observed similar results.
Secondly, we did not have specific information on the type or
brandofPPIandthedosesused.However,heterogeneityinrisk
associated with PPI type or dose would tend to bias our results
toward the null. In addition, compared with prescription data,
reports of regular use of PPI in the general questionnaire by
medical professionals are likely to be a better reflection of the
actual intake of the drug.
Thirdly, information about hip fracture is self reported and not
confirmed by medical records. However, our validation study
showed that self reported hip fracture is extremely reliable in
this cohort of medical professionals. Fourthly, we did not have
information about bone mineral density, but prior studies have
not demonstrated an association between PPI use and changes
inbonemineraldensity.
11 17 40Fifthly,ourstudyisobservational,
and we cannot exclude the possibility of residual confounding.
However, adjustment for the most important risk factors
previously identified for hip fracture did not appreciably alter
our results. Moreover, our data are remarkably consistent with
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RESEARCHthe risk estimates obtained from a systematic review of prior
studies.Finally,becauseoursamplesizewaslarge,itispossible
that even small differences in the prevalence of risk factors
could be statistically significant but may not be clinically
significant. However, our associations are reasonable in
magnitude, in line with other published estimates,
12 17 34 and
biologically plausible.
Conclusion and policy implication
In summary, regular use of PPI was associated with increased
risk of hip fracture among postmenopausal women, with the
strongest risk observed in individuals with the longest duration
of use or with a history of smoking. Our results, considered in
the context of a systematic review of prior studies, provide
compelling evidence of a significant association between PPI
use and fracture. Furthermore, in view of the steadily growing
prevalence of regular PPI use, our estimates of an absolute
increase in risk of five hip fractures per 10 000 person years
associated with PPI use suggest the potential for a high burden
of fractures attributable to PPIs across the population. These
findings further support the recent decision of the Food and
Drug Administration to revise labelling of PPIs to incorporate
concernsaboutapossibleincreaseinriskoffractureswiththese
drugs.
18Ourdatasuggesttheimportanceofcarefullyevaluating
the need for long term, continuous use of PPIs, particularly
among individuals with a history of smoking.
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RESEARCHTables
Table 1| Baseline characteristics of 79 899 postmenopausal women enrolled in the Nurses’ Health Study according to use of proton pump
inhibitors (PPIs) in 2000. Values are numbers (percentages) unless stated otherwise, and all variables are age adjusted (standardised to
the age distribution of the study population)
Regular PPI user (n=5341) Non-user of PPIs (n=74 558)
67.0 (7.0) 66.6 (6.9) Mean (SD) age (years)
28.2 (5.6) 26.6 (5.2) Mean (SD) body mass index (kg/m
2)
Smoking status*:
2194 (41.2) 32 983 (44.3) Never
2204 (41.3) 28 100 (37.7) Former use ≥10 years
544 (10.2) 6411 (8.6) Former use <10 years
202 (3.7) 3399 (4.5) Current use <15 cigarettes/day
185 (3.4) 3492 (4.7) Current use ≥15 cigarettes/day
12 (0.2) 173 (0.2) Missing data†
14.5 (13.2) 17.7 (15.6) Mean (SD) physical activity (METs-hour/week)‡
4.7 (7.7) 5.6 (8.5) Mean (SD) Alcohol intake (g/day)§
1001 (347) 982 (341) Mean (SD) Calcium intake (mg/day)§
Use of hormone replacement therapy:
2570 (48.1) 32 234 (43.2) Current
2481 (46.5) 37 920 (50.9) Former or never
290 (5.4) 4404 (5.9) Missing data†
31.0 22.0 History of osteoporosis
7.0 6.0 Use of bisphosphonate
11.0 5.0 Use of corticosteroid
24.0 15.0 Use of thiazide
461 (274) 443 (265) Mean (SD) vitamin D intake (IU/day)§
SD=standard deviation. METs=metabolic equivalents.
*Categories were selected based on prior studies.
†The missing data category could not be included in our multivariate models because the numbers of participants in the missing categories were too low. Thus,
in our models we carried forward values from prior questionnaires.
‡381 participants did not complete the physical activity assessment. For these participants, we assigned the median value of physical activity derived from the
entire cohort.
§1443 did not complete the semi-quantitative food frequency questionnaire. For these participants, we assigned the median value of calcium, alcohol, and vitamin
D derived from the entire cohort.
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RESEARCHTable 2| Risk of hip fracture according to use of proton pump inhibitors (PPIs) among 79 899 postmenopausal women enrolled in the
Nurses’ Health Study
Regular PPI user Non-users of PPIs
149/73 632 744/492 154 No of cases/No of person years
Hazard ratio (95% CI):
1.35 (1.13 to 1.62) 1.00 Adjusted for age
1.45 (1.21 to 1.73) 1.00 Adjusted for age + body mass index*
1.35 (1.12 to 1.62) 1.00 Adjusted for age + calcium intake†
1.37 (1.14 to 1.64) 1.00 Multivariable adjusted‡
1.36 (1.13 to 1.63) 1.00 Fully adjusted§
*Body mass index categorised as <20, 20–24.9, 25–29.9, ≥30 kg/m
2.
†Energy adjusted calcium intake calculated from diet and dietary supplements, categorised as <600, 600–899, 900–1200, >1200 mg/day.
‡Adjusted for age (months), body mass index, alcohol intake (<5, 5–15, >15 g/day), total energy adjusted calcium intake, level of physical activity (<1.7, 1.7–4.5,
4.6–10.6, 10.7–22.1, >22.1 metabolic equivalents-hours/week), smoking status (never, past ≥10 years, past <10 years, current <15 cigarettes/day, current >15
cigarettes/day), vitamin D intake (<400, 400–600, >600 IU/day), and history of osteoporosis (yes, no).
§Adjusted for age (years), body mass index, alcohol intake, total energy adjusted calcium intake, history of osteoporosis, level of physical activity, smoking status,
vitamin D intake, bisphosphonate use (yes, no), thiazide use (yes, no), corticosteroid use (yes, no), and use of postmenopausal hormone replacement therapy
(never, past, current).
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RESEARCHTable 3| Risk of hip fracture according to duration of use of proton pump inhibitors (PPIs) among 79 899 postmenopausal women enrolled
in the Nurses’ Health Study
Ptrend†
No of years of regular PPI use*
6–8 4 2 0
27/12 015 48/21 582 127/62 081 691/470 109 No of cases/No of person
years
Hazard ratio (95% CI):
<0.01 1.48 (0.99 to 2.20) 1.42 (1.05 to 1.92) 1.36 (1.12 to 1.65) 1.00 Age adjusted
<0.01 1.54 (1.03 to 2.31) 1.42 (1.05 to 1.93) 1.36 (1.12 to 1.65) 1.00 Multivariable adjusted‡
*Women who reported PPI use on a biennial questionnaire were assigned a duration of use of 2 years, and this variable increased in biennial increments (thus
women who reported PPI use on two biennial questionnaires were assigned a duration of use of 4 years, those who reported use on three questionnaires were
assigned a duration of 6 years, etc).
†Ptrend was estimated by entering the duration of regular PPI use in the model as a continuous variable.
‡Adjusted for age (months), body mass index, alcohol intake, total energy adjusted calcium intake, history of osteoporosis, level of physical activity, smoking status,
vitamin D intake, bisphosphonate use, thiazide use, corticosteroid use, and use of postmenopausal hormone replacement therapy (see table 2 for details).
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RESEARCHTable 4| Risk of hip fracture according to time since stopping use of proton pump inhibitors (PPIs) among 79 899 postmenopausal women
enrolled in the Nurses’ Health Study
Current PPI use
Stopped PPI use
Never used PPI <2 years ago ≥2 years ago
149/73 632 40/17 017 13/5028 691/470 109 No of cases/No of person years
Hazard ratio (95% CI):
1.38 (1.15 to 1.66) 1.54 (1.11 to 2.14) 1.09 (0.62 to 1.91) 1.00 Age adjusted
1.39 (1.15 to 1.68) 1.53 (1.10 to 2.12) 1.10 (0.63 to 1.92) 1.00 Multivariable adjusted*
*Adjusted for age (months), body mass index, alcohol intake, total energy adjusted calcium intake, history of osteoporosis, level of physical activity, smoking status,
vitamin D intake, bisphosphonate use, thiazide use, corticosteroid use, and use of postmenopausal hormone replacement therapy (see table 2 for details).
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RESEARCHTable 5| Risk of hip fracture according to use of proton pump inhibitors (PPI) in selected strata of 79 899 postmenopausal women enrolled
in the Nurses’ Health Study
Pinteraction* Regular PPI user Non-user of PPIs Stratum
Age
1.00 ≤65 years:
12/21 360 66/160 861 No of cases/No of person years
Hazard ratio (95% CI):
1.51 (0.80 to 2.86) 1.00 Age adjusted
1.34 (0.70 to 2.60) 1.00 Multivariable adjusted†
>65 years:
137/52 273 678/331 294 No of cases/No of person years
Hazard ratio (95% CI):
1.34 (1.10 to 1.61) 1.00 Age adjusted
1.36 (1.12 to 1.64) 1.00 Multivariable adjusted†
Body mass index
0.54 <25:
85/25 372 455/218 797 No of cases/No of person years
Hazard ratio (95% CI):
1.54 (1.21 to 1.95) 1.00 Age adjusted
1.45 (1.14 to 1.85) 1.00 Multivariable adjusted†
≥25:
64/48 260 289/273 357 No of cases/No of person years
Hazard ratio (95% CI):
1.30 (0.99 to 1.72) 1.00 Age adjusted
1.23 (0.93 to 1.64) 1.00 Multivariable adjusted†
Postmenopausal hormone use
0.72 Never or previously used:
125/54 534 625/350 735 No of cases/No of person years
Hazard ratio (95% CI):
1.36 (1.11 to 1.66) 1.00 Age adjusted
1.36 (1.11 to 1.66) 1.00 Multivariable adjusted†
Currently used:
24/19 099 119/141 419 No of cases/No of person years
Hazard ratio (95% CI):
1.44 (0.91 to 2.28) 1.00 Age adjusted
1.36 (0.84 to 2.19) 1.00 Multivariable adjusted†
Smoking status
0.03 Never:
49/31 829 322/220 553 No of cases/No of person years
Hazard ratio (95% CI):
1.07 (0.78 to 1.45) 1.00 Age adjusted
1.06 (0.77 to 1.46) 1.00 Multivariable adjusted†
Current or past:
100/41 803 422/271 600 No of cases/No of person years
Hazard ratio (95% CI):
1.54 (1.23 to 1.93) 1.00 Age adjusted
1.51 (1.20 to 1.91) 1.00 Multivariable adjusted†
Corticosteroid use
0.10 User:
40/9816 71/29 054 No of cases/No of person years
Hazard ratio (95% CI):
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RESEARCHTable 5 (continued)
Pinteraction* Regular PPI user Non-user of PPIs Stratum
1.87 (1.22 to 2.86) 1.00 Age adjusted
2.09 (1.32 to 3.30) 1.00 Multivariable adjusted†
Non-user:
109/63 817 673/463 101 No of cases/No of person years
Hazard ratio (95% CI):
1.19 (0.97 to 1.47) 1.00 Age adjusted
1.26 (1.02 to 1.55) 1.00 Multivariable adjusted†
History of osteoporosis
0.76 Yes:
62/45 687 392/353 613 No of cases/No of person years
Hazard ratio (95% CI):
1.25 (0.98 to 1.60) 1.00 Age adjusted
1.28 (1.00 to 1.64) 1.00 Multivariable adjusted†
None:
87/27 945 352/138 542 No of cases/No of person years
Hazard ratio (95% CI):
1.31 (1.00 to 1.73) 1.00 Age adjusted
1.41 (1.07 to 1.87) 1.00 Multivariable adjusted†
Calcium intake
0.38 ≥900 mg/day:
79/42 070 371/274 346 No of cases/No of person years
Hazard ratio (95% CI):
1.41 (1.10 to 1.82) 1.00 Age adjusted
1.42 (1.10 to 1.83) 1.00 Multivariable adjusted†
<900 mg/day:
70/31 563 373/217 810 No of cases/No of person years
Hazard ratio (95% CI):
1.26 (0.97 to 1.64) 1.00 Age adjusted
1.25 (0.95 to 1.64) 1.00 Multivariable adjusted†
*We evaluated effect modification using cross classified categories of hip fracture risk factors and PPI use. We tested significance of interactions using the
log-likelihood ratio test comparing the model with cross classified categories with a model that included the risk factors as independent variables.
†Adjusted for same variables as Table 3 minus the stratum covariate.
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RESEARCHFigure
Results of meta-analysis of our results with 10 published studies of risk of hip fracture with chronic use of a proton pump
inhibitor (PPI). For the study by Yu et al,
13 risk estimates were only provided for men and women separately
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e372 doi: 10.1136/bmj.e372 (Published 31 January 2012) Page 13 of 13
RESEARCH